Tardy marketing application filing, trial failure troubles Supernus investors

Two key updates surfaced in CNS-focused Supernus Pharmaceuticals third-quarter results on Tuesday.

The drugmaker has not yet filed a marketing application for its ADHD drug SPN-812 — and a late-stage study testing another therapy, SPN-810, for use in impulsive aggression (IA) in patients with ADHD, has failed.